Recently, the president announced Alex Azar as his nominee to lead the US Department of Health and Human Services, saying: “He will be a star for better healthcare and lower drug prices!” People like me – experts in drug policy and advocates for lowering drug costs for American patients – know that nothing could be farther from the truth.
On average, Americans pay twice as much for life-saving drugs as consumers in other developed countries. It doesn’t have to be this way, but unfortunately, Azar might think so.
On Wednesday, Azar appeared before the Senate Health, Education, Labor and Pensions committee. While he stated his commitment to lowering drug prices, he declined to support the two solutions that would have the greatest impact on patients. In fact, he and his company have vigorously opposed policies that would make healthcare more affordable for the rest of us. (more…)
Today, Democrats are ecstatic, Republicans perhaps not so much, but one thing is certain: everyone’s wallets are cheering! The verdict is in: the state of Alabama voted Doug Jones to represent them as the next Senator of Alabama.
Put the Drama Aside…
You see, Doug Jones is a vote for expressly permitting your access to cheaper meds in Canada. “The Affordable and Safe Prescription Drug Importation Act” is a bill that Roy Moore would have most assuredly voted against, which is frankly unacceptable given the exorbitant prescription medication costs folks are facing at the local pharmacy counter every day.
Yesterday, a bill was introduced in the U.S. Senate called the Affordable and Safe Prescription Drug Importation Act, which, if passed, would legalize the importation of lower cost medications from Canada, by wholesalers for re-sale and individuals for personal use. I support this bill as a great step in the right direction to reign in drug prices. The bill’s sponsors, Senators Bernie Sanders (I-VT), Cory Booker (D-NJ), and Bob Casey (D-PA) are to be commended. Congressmen Elijah E. Cummings (D-MD) and Lloyd Doggett (D-TX) introduced a companion bill in the House. You can watch the press conference announcing the new importation legislation above.
If passed, the new bill directs the FDA to finally help Americans do what they do already, but they would have new FDA assurances, which is purchase lower cost medication from safe international online pharmacies. It also would allow wholesalers in the U.S. to buy medications at lower cost from FDA-registered Canadian wholesalers, so that U.S. retail pharmacies can charge lower prices, too, which will mean fewer international, online retail sales.
For the last 15 years, we’ve been verifying international online pharmacies, ones that extend beyond Canada, and comparing their prices. Empirical and peer-reviewed literature studying online pharmacies demonstrates the significant savings consumers find through safe importation. We know for a fact this works. (more…)
In this blog post I’m going to get personal. Not about me but about importing medication from Canada and other countries. You’ll see what I mean. Last week, Senator Bernie Sanders introduced an amendment to the budget bill, which would have paved the way for future deficit neutral spending to implement new regulations expanding lawful access to lower cost imported medication from wholesalers, pharmacies and individuals. Unfortunately, the amendment was defeated 52-46.
Let’s forget about the fact that drug companies give members of Congress lots of money. OK, I can’t forget: it’s about two billion dollars over the last 15 years. Some senators who voted against the amendment cited their concerns with safety as a basis for their vote. Let me explain why they are wrong, at least when it comes to personal vs. wholesale drug importation. (more…)
Many of you know that in other countries, such as Australia and Canada, government agencies negotiate with pharmaceutical companies through myriad policy interventions to keep prescription drugs affordable for their citizens. This article explains how that’s done, why it works – but also identifies the tradeoffs where in some cases a new drug is not available outside the U.S. because regulators decide it doesn’t offer additional value over existing drugs.
It also addresses the issue of how research and development to find new drugs may be negatively affected if the U.S. institutes more control over drug prices. Some people argue that broader access to currently available drugs at lower prices means fewer new breakthrough drugs coming to market. [EDIT 12/9/2016: I wanted to make clear that many people do not agree with this position and argue that more drug company profits are spent on marketing and advertising than on research and development and the pharmaceutical industry greatly exaggerates the prospects of less innovation due to drug price controls].
In speaking with lots of people on different sides of the political spectrum and with contrasting governing philosophies — everyone agrees that us Americans are getting a bad deal on drug prices right now. This VOX piece really speaks to the issues at hand, objectively and truthfully, and if you’re interested in “getting it” you should read it.